Precision Neuroscience, founded by Neuralink alums, is developing a competing brain implant that it says is safer

In an unexpected corner of Manhattan, Precision Neuroscience is quietly working on a groundbreaking brain-computer interface that could redefine how humans interact with technology. Founded in 2021 by a team that includes former Neuralink members, the company aims to create a safer and less invasive alternative to existing brain implants. Precision Neuroscience is focused on developing a device that facilitates direct communication between the brain's electrical signals and computers. This innovative technology has gained momentum in recent years, largely due to advancements in artificial intelligence, which have enhanced our understanding of brain functionality. At an AI conference earlier this year, Craig Mermel, the company's president and chief product officer, explained how AI has propelled the field of neuroscience, allowing for the collection of intricate data about brain activities. Precision stands out among a wave of startups in the tech space, as it focuses on hardware solutions rather than software tools. The brain-computer interface, known as the "Layer 7 Cortical Interface," is designed to assist those with severe paralysis in regaining independence. Co-founder Ben Rapoport, a neurosurgeon and electrical engineer, emphasized the importance of helping individuals who can think clearly but struggle with movement. This device aims to enable users to communicate, use computers, and perform everyday tasks by translating neural commands into actions. The Layer 7 Cortical Interface is remarkably thin, approximately one-fifth the width of a human eyelash. It features 1,024 electrodes that can both record and stimulate brain activity. Unlike traditional implants that require invasive procedures, Precision's device rests on the brain's surface, minimizing potential damage and offering a detailed insight into brain function. Rapoport, who previously worked with Neuralink, left due to concerns about the safety and scalability of brain-computer interface technologies. He believes that Precision's approach, which avoids damaging brain tissue, is essential for the clinical viability of such devices. While Neuralink's implant involves surgical insertion into the brain, Precision's method is designed to be less invasive, employing a "cranial microslit" technique to place its interface on the brain's surface. This innovative approach allows for easy replacement and adjustment of the device as needed. In 2023, Precision launched its first clinical studies, recruiting 47 volunteers undergoing brain surgery for other reasons. The goal is to gather comprehensive data on brain activity during various tasks, allowing AI algorithms to learn and interpret neural patterns. Currently, the company has received FDA clearance to use its electrode array for monitoring and stimulating brain activity. They anticipate further clinical studies to refine their technology and explore its potential applications, which could extend beyond aiding paralyzed individuals to include surgical assistance and treatments for conditions like depression. As Precision Neuroscience continues to advance, they are building a robust neural model aimed at decoding thoughts and intentions, paving the way for a future where brain-computer interfaces could seamlessly integrate with everyday technology. Rapoport's vision is clear: to create a safe and effective solution that could ultimately benefit a wider audience, far beyond its initial target group.